MicroVision Announces Third Quarter 2020 Results
MicroVision, Inc. (NASDAQ:MVIS) reported third-quarter 2020 revenue of $0.6 million, down from $1.2 million in Q3 2019. The company's net loss narrowed to $2.8 million ($0.02 per share) compared to a loss of $6.1 million ($0.05 per share) in the same quarter last year. Cash and equivalents totaled $5.0 million, a decrease from $5.8 million at the end of Q4 2019. CEO Sumit Sharma emphasized the pursuit of a strategic transaction that accurately reflects the value of their technology and thanked shareholders for their support during the recent special meeting.
- Narrowed net loss to $2.8 million from $6.1 million year-over-year.
- CEO's commitment to pursuing strategic transactions for shareholder value.
- Revenue decreased by 50% compared to Q3 2019.
- Cash and cash equivalents reduced from $5.8 million to $5.0 million since last quarter.
REDMOND, Wash., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display and sensing technology, today announced its third quarter 2020 results.
Revenue for the third quarter of 2020 was
“MicroVision is focused on pursuing a strategic transaction at the right value for our shareholders. Our focus is to drive to an agreement at a valuation that reflects the sustainable strategic advantage, we believe, our technology offers now and into the future. We are continuing to work towards this goal while maintaining expenses at appropriate levels. We appreciate the strong support of our shareholders, as evidenced by the vote at our special shareholders meeting on October 8th as we continue the work ahead,” said Sumit Sharma, MicroVision's Chief Executive Officer.
Financial Results Webcast
MicroVision will host a webcast which will start at 2:00 p.m. Pacific Time on Thursday, October 29, 2020 by accessing the Investor Relations section of MicroVision’s website on the Investor Relations Events Calendar page at https://microvision.gcs-web.com/investor-event-calendar. Investors may submit questions for management in advance to IR@MicroVision.com or beginning 10 minutes before or during the live webcast on October 29, 2020.The webcast will be available for rebroadcast from the Investor Relations section of MicroVision’s website on the Investor Relations Events Calendar page.
About MicroVision
MicroVision is the creator of PicoP® scanning technology, an ultra-miniature sensing and projection solution based on the laser beam scanning methodology pioneered by the Company. MicroVision’s platform approach for this sensing and display solution means that its technology can be adapted to a wide array of applications and form factors. We combine our hardware, software, and algorithms to unlock value for our customers by providing them a differentiated advanced solution for a rapidly evolving, always-on world.
Extensive research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and has been included in the Ocean Tomo 300 Patent Index. The Company is based in Redmond, Washington.
For more information, visit the Company’s website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc or follow MicroVision on Twitter at @MicroVision.
MicroVision® and PicoP® are registered trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Forward-Looking Statements
Certain statements contained in this release, including those relating to the value of our technology, timing of products coming to market, management of finances, exploration of strategic alternatives with third parties and the Company’s future products and product applications are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the risk that the Company may not succeed in finding licensing or other strategic solutions, including a potential sale of the Company, with acceptable timing, benefits or costs, our ability to operate with limited cash or to raise additional capital when needed; market acceptance of our technologies and products or for products incorporating our technologies; the failure of our commercial partners to perform as expected under our agreements, including from the impact of the COVID-19 (coronavirus); our ability to identify parties interested in paying any amounts or amounts we deem desirable for the purchase or license of intellectual property assets; our or our customers’ failure to perform under open purchase orders, our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; our ability to maintain our listing on the Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect us to a greater extent than indicated. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
| MicroVision, Inc. | ||||||
| Balance Sheet | ||||||
| (In thousands) | ||||||
| (Unaudited) | ||||||
| September 30, | December 31, | |||||
| 2020 | 2019 | |||||
| Assets | ||||||
| Current Assets | ||||||
| Cash and cash equivalents | ||||||
| Accounts receivable, net | - | 1,079 | ||||
| Inventory | - | 192 | ||||
| Other current assets | 748 | 729 | ||||
| Total current assets | 5,775 | 7,837 | ||||
| Property and equipment, net | 1,515 | 1,849 | ||||
| Operating lease right-of-use asset | 1,040 | 1,308 | ||||
| Restricted cash | 435 | 435 | ||||
| Intangible assets, net | 178 | 221 | ||||
| Other assets | 18 | 186 | ||||
| Total assets | ||||||
| Liabilities and Shareholders' Equity (Deficit) | ||||||
| Current Liabilities | ||||||
| Accounts payable | ||||||
| Accrued liabilities | 295 | 2,045 | ||||
| Deferred revenue | - | 21 | ||||
| Contract liabilities | 8,160 | 9,755 | ||||
| Other current liabilities | - | 83 | ||||
| Current portion of long-term debt | 961 | - | ||||
| Current portion of operating lease liability | 671 | 656 | ||||
| Current portion of finance lease obligations | 15 | 25 | ||||
| Total current liabilities | 11,615 | 14,456 | ||||
| Long term debt, net of current portion | 617 | - | ||||
| Operating lease liability, net of current portion | 922 | 1,348 | ||||
| Finance lease obligations, net of current portion | - | 9 | ||||
| Total liabilities | 13,154 | 15,813 | ||||
| Commitments and contingencies | ||||||
| Shareholders' Equity (Deficit) | ||||||
| Common stock at par value | 144 | 126 | ||||
| Additional paid-in capital | 578,326 | 568,496 | ||||
| Accumulated deficit | (582,663) | (572,599) | ||||
| Total shareholders' equity (deficit) | (4,193) | (3,977) | ||||
| Total liabilities and shareholders' equity (deficit) | ||||||
| MicroVision, Inc. | |||||||||||||||||
| Statement of Operations | |||||||||||||||||
| (In thousands, except earnings per share data) | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| Three month ended September 30, | Nine months ended September 30, | ||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||
| Product revenue | $ | 100 | $ | 999 | $ | 1,347 | $ | 1,198 | |||||||||
| License and royalty revenue | 539 | 17 | 1,323 | 17 | |||||||||||||
| Contract revenue | - | 174 | 25 | 3,066 | |||||||||||||
| Total revenue | 639 | 1,190 | 2,695 | 4,281 | |||||||||||||
| Cost of product revenue | - | 2,039 | 1,394 | 3,352 | |||||||||||||
| Cost of contract revenue | - | 33 | 4 | 1,786 | |||||||||||||
| Total cost of revenue | - | 2,072 | 1,398 | 5,138 | |||||||||||||
| Gross margin | 639 | (882 | ) | 1,297 | (857 | ) | |||||||||||
| Research and development expense | 1,972 | 3,566 | 7,262 | 15,484 | |||||||||||||
| Sales, marketing, general and administrative expense | 1,485 | 1,697 | 4,536 | 6,851 | |||||||||||||
| Gain on disposal of fixed assets | - | - | (450 | ) | - | ||||||||||||
| Total operating expenses | 3,457 | 5,263 | 11,348 | 22,335 | |||||||||||||
| Loss from operations | (2,818 | ) | (6,145 | ) | (10,051 | ) | (23,192 | ) | |||||||||
| Other expense, net | (8 | ) | 4 | (13 | ) | (7 | ) | ||||||||||
| Net loss | $ | (2,826 | ) | $ | (6,141 | ) | $ | (10,064 | ) | $ | (23,199 | ) | |||||
| Net loss per share - basic and diluted | $ | (0.02 | ) | $ | (0.05 | ) | $ | (0.07 | ) | $ | (0.21 | ) | |||||
| Weighted-average shares outstanding - basic and diluted | 143,685 | 114,874 | 137,027 | 107,953 | |||||||||||||
Investor Relations Contact
David H. Allen
Darrow Associates, Inc.
408.427.4463
dallen@darrowir.com
FAQ
What were MicroVision's Q3 2020 revenue figures?
How much did MicroVision lose in the third quarter of 2020?
What was MicroVision's cash position at the end of Q3 2020?
What did MicroVision's CEO say about the company's future plans?
What are the key financial metrics from MicroVision's Q3 2020 report?
